Ajanta Pharma Q2FY26 Earnings Results Out: Company Declares ₹28 Interim Dividend

Written by: Aayushi ChaubeyUpdated on: 3 Nov 2025, 8:30 pm IST

As per Ajanta Pharma Q2FY26 earnings results, increasing sales of generic medicines has led to a 20% growth in net profit this quarter.

As per Ajanta Pharma Q2FY26 earnings results, the company’s branded generics business has outperformed the Indian Pharmaceutical Market (IPM). Driven by robust growth in ophthalmology and dermatology, its business has exceeded industry growth by 32%.

How Does the Ajanta Pharma Q2FY26 Earnings Results Fare Against Q2FY25?

Financial Metric (₹ crore)	Q2FY26	Q2FY25	YoY Change
Revenue from Operations	1,354	1,187	+14%
EBITDA	328	312	+5%
Net Profit	260	216	+20%

Segment-Wise Breakdown of Ajanta Pharma Q2FY26 Earnings Results

For the quarter ended September 30, 2025, Ajanta Pharma reported a 20% rise in consolidated net profit and a 14% increase in revenue.

Segment	Q2FY26 Revenue (₹ crore)	YoY Growth
India – Branded Generics	432	+12%
US – Generics	344	+48%
Consolidated Revenue (H1FY26)	2,656	+14% (YoY)
Net Profit (H1FY26)	516	+12% (YoY)

Ajanta Pharma Declares ₹28 Dividend

Ajanta Pharma’s Board of Directors approved the first interim dividend for FY26 at ₹28 per equity share of ₹2 each. The total dividend payout amounts to ₹349.82 crore.

The company fixed November 10, 2025, as the record date, and the dividend will be paid on or after November 20, 2025. Investors with a demat account must hold the shares of Ajanta Pharma as of November 10, 2025, to be eligible for this dividend. This dividend reflects the company’s commitment to rewarding its shareholders while maintaining a strong balance sheet.

Conclusion

Ajanta Pharma’s Q2FY26 results reflect a period of solid growth supported by its strong product portfolio, consistent expansion in key markets, and efficient operations. With a healthy dividend and rising contributions from both domestic and international businesses, the company remains well-positioned for continued growth in the coming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

Published on: Nov 3, 2025, 2:57 PM IST

Aayushi Chaubey

Aayushi Chaubey is a finance enthusiast with a year of experience in the market research industry. She loves to decipher the impact of real-world developments on stock markets and how investors can make smart investment decisions to meet their long-term goals.

Know More